Dental Implant Market in India 2014, New Report Launched

Dental Implant Market in India 2014 report states that the demand for dental implant is rising in the country due to various reasons. The huge population of the country comprising a large number of elderly people has resulted in a strong case for the growth of dental services. The number of dental clinics being set up in the country has been increasing and is making dental services more accessible and affordable; in turn leading to a rise in the demand for dental implant. With a large number of patients suffering from edentulism and awareness about the advantages of dental implant growing, demand for this product is expected to grow strongly in the coming years. Growth in dental tourism is another factor aiding growth in the market since the entire dental implant procedure costs much lesser in India compared to the developed Western countries.

The dental implant market in India is characterized by the presence of very few players with mostly foreign companies operating in this market. High competitive rivalry exists between the foreign manufacturers while the Indian companies are still looking to make a mark in the industry. Overall, the market is exhibiting steady growth and promises ample opportunities to all the players operating in the market. Efforts to develop cheap dental implants are in progress and any breakthrough in this effort will help the market to grow further.

Spanning over 83 pages, “Dental Implant Market in India 2014” report covering the Executive Summary, Introduction, Market Overview, Product Prices, EXIM, Drivers & Challenges, Competitive Landscape, Strategic Recommendation, Appendix. The report covered companies are - Siemens Ltd., Alps International Pvt. Ltd., Elkon Pvt. Ltd., Starkey Laboratories India Pvt. Ltd., Unitron Hearing India Pvt. Ltd, Widex India Pvt. Ltd., Phonak India Pvt. Ltd., Bernafon AG

For more information see - http://mrr.cm/444

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Oncology Pharmaceuticals Market in India 2014, New Report Launched

Oncology Pharmaceutical Market in India 2014 report highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing number of cancer cases are the key drivers of this market. Lung, stomach, colon and breast cancer cause the maximum number of cancer deaths each year. Pharmaceutical companies are progressively increasing R&D expenditure on cancer vaccines. The growing number of patients seeking treatment for cancer has made hospitals realize that cancer treatment is an important area for growth. Gleevec, Mabthera, Iressa, Avastin, Grafeel, Soliris and Herceptin are the top selling cancer drugs in the Indian market.

Alternative therapies such as cancer gene therapy and cancer cell therapy are increasingly becoming popular in cases where conventional therapies have failed. Combination therapies are being increasingly used in cancer treatments. Some challenges faced by the industry are the internal competition between large pharmaceutical companies. Another challenge is the penetration of Oncological drugs in rural areas which is very low. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well. Manufacture of generic oncology drugs will help the pharmaceutical manufacturer gain a competitive advantage over others in a highly competitive pharma market. Companies should focus on development of new molecules in order to prolong the longevity of a blockbuster drug in the market.

Spanning over 90 pages, “Oncology Pharmaceuticals Market in India 2014” report covering the Executive Summary, Introduction, Market Overview, Export-Import, Value Chain, Drivers & Challenges, Government Initiatives, Government Initiatives, Regulations, Competitive Landscape, Recent Developments, Strategic Recommendation, Appendix. The report covered companies are - Sanofi India Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Novartis India Ltd., Merck Ltd., Pfizer Ltd., Ranbaxy Laboratories Ltd., Johnson and Johnson Ltd., Roche Pharmaceuticals Pvt. Ltd.

For more information see - http://mrr.cm/4Zv

Find all Oncology Reports at: http://www.marketresearchreports.com/oncology

Nuclear Imaging - PET and SPECT Equipment - Global Analysis and Market Forecasts, New Report Launched

Nuclear Imaging Market Overview

Publisher estimates the global nuclear imaging market to have been worth $1.77 billion in 2012 and $1.83 billion in 2013. Publisher estimates that this market will be worth $2.2 billion in 2020, increasing at a Compound Annual Growth Rate (CAGR) of 3.3% during the period of 2014 to 2020.

The key drivers for the global nuclear imaging market are:

• Aging population and increasing disease prevalence
• Increasing referring physician awareness
• Increasing defensive medicine
• Increasing patient awareness
• Increasing self-referral behavior
• Increasing implementation of comparative effectiveness research
• Improved accreditation of imaging facilities
• Availability of new imaging reagents
• Increasing demand for cancer diagnoses
• Increasing demand for imaging-based companion diagnostics
• Replacement of positron emission tomography (PET)/computed tomography (CT) by PET/magnetic resonance imaging (MRI)
• Replacement of single-photon emission computed tomography (SPECT)-only systems

The key barriers of the global nuclear imaging market are:

• Legislation affecting reimbursements
• The lobbying efforts of medical insurance companies and consequent reduction in the number of procedures performed
• Greater scrutiny of electronic medical records by healthcare payers, leading to a reduction in the number of procedures performed.
• Increased use of appropriateness criteria, resulting in reduced examinations
• Practice guidelines reducing unnecessary procedures
• Loss of nuclear medicine skills
• High cost of instruments and reagents
• Supply difficulties and increasing cost of radio-pharmaceuticals
• Medical Device Excise tax increasing development costs
• Hospital consolidation reducing the number of scanning facilities

The nuclear imaging market is a moderately growing market with a 2014-2020 CAGR of 3.3% globally. It is a mature sector of the diagnostic imaging market; continued growth is expected along with continued technological developments and the emerging markets’ acceptance of products.

US Dominates the Nuclear Imaging Market

In 2012, the US dominated the global nuclear imaging market, accounting for 69% of sales globally. The market is dominated by three companies: the market leader is Philips Healthcare with around 35% of the market by revenue, followed closely by GE Healthcare with around 33% of the market, and Siemens Healthcare at just under 30%.

Demand for Nuclear Imaging in US to Become Static

The US is the largest market for nuclear imaging, in terms of the number of systems sold and the number of procedures carried out. However, a period of a rapid increase in procedures in the US, particularly PET and PET/CT, has led to measures to reduce the number of procedures that can be reimbursed, and thus reduce the demand for nuclear imaging systems. Prior to healthcare reform, the major threat to the US nuclear imaging market was the limited supply of radiopharmaceuticals.

APAC to Foster Future Growth

APAC economies. especially China and Japan, will continue to provide immense opportunities for increasing sales within the global nuclear imaging market. Publisher projects that Japan will increase its market share by 75% and that China will almost double its market share.

Publisher expects that the growth of sales in China will be attributed in part to the sale of more PET/CT and SPECT/CT systems, whereas in Japan, growth will be due to increasing demand for SPECT/CT and PET/MRI systems.

Future Outlook

The economic downturn has been a continued concern within the whole of the diagnostic imaging market. Indeed, the high cost of nuclear imaging equipment and procedures has made the nuclear imaging market more susceptible to the downturn. The market growth for nuclear imaging in the US and EU is heavily dependent on the replacement of already existing systems because, as is the case in most of the developed countries, the capacity for new installations is limited. As the US and EU economies recover, it can be expected that the equipment will be replaced.

However, at this point in time, the key opinion leaders (KOLs) that Publisher interviewed for this report indicated that not all equipment is replaced at the end of the average product lifecycle, negatively affecting sales in the US and EU markets.

The rising prevalence of disease, an aging population, and a growing global population will act as major drivers of the increased use of nuclear imaging. However, cost-containment measures implemented by healthcare authorities will affect which nuclear imaging technologies are favored.

For more information see – http://mrr.cm/4Z9

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices

Healthcare, Regulatory and Reimbursement Landscape - South Africa, New Report Launched

The healthcare market in South Africa is growing due to high prevalence of chronic indications, regulatory reforms and new healthcare policies. However, the pricing policies that promote the dispensing of low cost drugs are hindering the growth of the pharmaceutical market.

In 2013, the population was approximately 53 million, having grown at a Compound Annual Growth Rate (CAGR) of 1.7% from 2008. Due to improvements in healthcare facilities, the elderly population has been increasing and as of 2013 comprised 5.2% of the entire population (STATSSA, 2008; STATSSA, 2009; STATSSA, 2010; STATSSA, 2011; STATSSA, 2014g).

Infectious diseases such as HIV/AIDS and Tuberculosis (TB) have high prevalence rates in South Africa. In 2011, approximately 11.2% of the total population was infected with HIV. In 2009, the TB incidence rate was 971 per 100,000 population, and the prevalence of non-communicable diseases such as cardiovascular, renal and respiratory diseases has increased due to changes in lifestyle (HST, 2011). These are the driving factors for the growth in the pharmaceutical market.

In 2006, the government introduced the Free Healthcare for All policy, under which free healthcare will be provided to all South Africans in all public healthcare facilities (Harrison, 2009). This has increased the usage of healthcare facilities, which has in turn increased pharmaceutical consumption. In 2013, the government proposed revisions to its intellectual property rights policy to both enforce patent protection and increase the accessibility of medicines, which is currently under review (Médecins Sans Frontières, 2014). The government also introduced National Health Insurance (NHI) in 2011, which is expected to further promote the use of healthcare facilities.

In South Africa, the price that a manufacturer can charge for a drug is based on a Single Exit Price (SEP), which is the price decided by the government after selecting the lowest price of the drug in Australia, Canada, New Zealand, and Spain. The pharmacies get the drug at the SEP and the pharmacists add a markup. The pharmacists are allowed to charge the highest markups on the medicines with the lowest cost. This promotes the dispensing of low cost generics over branded drugs, hindering the growth of pharmaceutical market.

In 2013, the pharmaceutical market was worth approximately $3.4 billion. It is set to grow at a CAGR of 7.0% from 2014 to $5.6 billion in 2020 (WESGRO, 2014).

In 2008, the medical device market was valued at $1.6 billion and grew at a CAGR of 4.3% to $1.9 billion in 2013. It is estimated to reach a value of $2.6 billion by 2020. The major market segments in medical device market were ophthalmic devices, orthopedic devices, In Vitro Diagnostics (IVD), cardiovascular devices and, nephrology and urology devices. The major players in the medical device market include Siemens Healthcare, Essilor, B.Braun, Roche and Covidien. In 2008, the diagnostic market was valued at $1 billion and grew at a CAGR of 4.5% to $1.2 billion in 2013.

Universal healthcare services are hindered by a significant shortage of healthcare professionals in the public sector, delays in the full implementation of NHI and an uneven distribution of healthcare resources.

Around 84% of the population relies on public healthcare. These high numbers have overburdened the public healthcare sector leading to a reduction in the quality of care along with increased scarcity of healthcare personnel (DoH, 2011a).

The government is trying to overcome this shortage through the introduction of NHI, which will make both public and private sector facilities available to all. NHI was introduced in 2011 and will be implemented in three phases spanning 14 years. The third and final phase of NHI implementation will end in 2025 by which time, the government hopes that the entire South African population will be covered. NHI is currently in its first phase of implementation and the government is testing it on a pilot scale. Since the NHI is being implemented over such a long period, it will not contribute to the immediate improvement of the healthcare system.

In 2013, there were 370 doctors per 100,000 population in South Africa (HST, 2011). This is higher than the 336 doctors per 100,000 population available on average in the EU and the 178 doctors per 100,000 population available on average in upper-middle-income countries. Although the doctor to population ratio is higher in South Africa than the EU average, the accessibility of healthcare is limited. This is due to the uneven distribution of healthcare personnel as most doctors work in the private sector. Most doctors also prefer working in developed urban areas to rural areas due to the superior infrastructure and economic environment. Since the majority of the population lives in these rural areas, a large section of population does not have access to healthcare facilities.

The South African government is planning to overcome the problem of delayed drug approvals through the establishment of new regulatory bodies.

The Medicines Control Council (MCC) regulates the pharmaceutical market in South Africa. On average, the organization requires three to four years for the drug approval process, in comparison to developed countries, which usually take only a year to approve a drug, which is very low. To overcome this problem the government is replacing the MCC with a new regulatory body called South Africa Health Products Regulatory Authority (SAHPRA). SAHPRA is expected to speed up the drug approval process and reduce timelines while maintaining the highest standards of quality (Khan, 2014).

Although, the political environment is stable, a continual growth in the economy is essential for the overall growth of South Africa.

The political stability in South Africa is not reflected in the economic sustenance. Although the government’s primary goal is to achieve economic equality, South Africa is still ranked among the top 10 countries in the world for income disparity. This is a result of the lingering effects of apartheid, with black South Africans making up the majority of the low-income population still living on basic amenities only (CIA, 2014a; World Bank, 2014a).

South Africa also has a very high unemployment rate, estimated at 24.9% in 2013 (STATSSA, 2013f). In 2013, the Gross Domestic Product (GDP) per capita was $6,621 and is expected to reach $8,471 in 2020 at a CAGR of 4.3% (IMF, 2014a). Gross National Income (GNI) per capita was estimated at $7,190 in 2013 (World Bank, 2014d). This increase in GDP and GNI per capita represents the improving economic condition of the country.

South Africa hopes that promoting entrepreneurship and industrialization combined with employment equity policies that focus on improving job opportunities for black South Africans will solve the problem of high unemployment rate.

For more information see – http://mrr.cm/4Zj

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Healthcare, Regulatory and Reimbursement Landscape - Singapore, New Report Launched

Singapore’s healthcare market is driven by universal access to health insurance schemes and world-class biomedical sciences research facilities, although the healthcare market is small in comparison to those of other developed countries, due primarily to the limited size of its population.

The value of the pharmaceuticals market in Singapore increased from $489m in 2008 to $761m in 2013 at a Compound Annual Growth Rate (CAGR) of 9.3% and is expected to increase further from $776m in 2014 to $873m in 2020 at a CAGR of 2.0% (Tarn et al., 2008; DoS, 2014; EDB, 2014c).

Universal healthcare coverage covers 100% of the population. The five types of healthcare insurance plans available are Medisave, MediShield, Medisave-Approved Integrated Shield Plans, MediFund and ElderShield.

Singapore is known for its world-class biomedical sciences research facilities for the development of the pharmaceutical and medical device markets at medical technology hubs such as Medtech, Biopolis and Tuas biomedical park. The country has emerged as a regional hub for the manufacture and R&D activities of multinational pharmaceutical companies and offers excellent opportunities for Biomedical Sciences (BMS) companies via a pro-business environment, low unit labor costs, low corporate tax, and strong government support. The BMS industry consists of four sectors: pharmaceuticals, medical technology, biotechnology, and healthcare services. The BMS Industry Partnership Office (IPO) was established in 2010 and includes the National Medical Research Council, Ministry of Health (MoH), A*STAR and the Singapore Economic Development Board (EDB).

Singapore is a small country with a total population of approximately 5.4 million as of 2013 (DoS, 2014), which is less than in neighboring countries Indonesia (248 million) and Malaysia (29.9 million) (IMF, 2014f; IMF, 2014g). Domestic companies have fewer opportunities for permanent establishment due to the limited patient population, which in turn has a negative effect on the revenue generated by domestic companies, ultimately impeding pharmaceutical market growth.

The medical device market is expected to grow as Singapore strengthens its position as the region’s healthcare hub. Medical devices are imported primarily from the US, Japan and Germany (ITA, 2014). Products such as syringes, catheters and research instruments are manufactured domestically. In 2011, the output of the medical technology sector was SGD4.3 billion ($3.4 billion) and this total is expected to reach SGD5 billion ($4 billion) in 2015 (EDB, 2014a).

Singapore offers a transparent regulatory system for the drug and medical device approval application process and a strong Intellectual Property (IP) protection framework.

Singapore offers a transparent drug and medical device approval application process system with a strong intellectual property protection law. The regulatory agency for IP - the Intellectual Property Office of Singapore - is efficient and operates in a very transparent way, making it relatively straightforward for owners to protect their IPs. Singapore is ranked number one in Asia and second in the world for strong IP protection in the world, followed by Finland (IPOS, 2014a). This will help companies to protect their IP and attract them to invest in the healthcare market.

Efficient healthcare infrastructure and increasing public healthcare expenditure is expected to drive the healthcare market in Singapore.

In 2010, Singapore was ranked fourth globally for its healthcare infrastructure. The MoH is responsible for providing for the healthcare service needs of the people, through policy planning and co-ordination. Singapore’s healthcare institutions consist of public hospitals, private hospitals and specialty centers, covering the entire spectrum of clinical services, from basic health screening to dental surgery and quaternary care.

The MoH has restructured the healthcare system into an integrated care model in order to provide patients with integrated care facilities. Singapore’s healthcare system is split into six regional healthcare systems, which are supported by a regional hospital providing primary to long-term care services. Various healthcare clusters such as SingHealth and Alexandra Health have also been set up by the government to provide integrated services for patients.

Singapore’s Healthcare 2020 Masterplan aims to enhance the accessibility and quality of the healthcare system for the people so that anyone in need of healthcare services can receive the attention required within an appropriate time frame (MoH, 2012).

In 2008, the public-sector health expenditure share was approximately 30.2%, which increased to an estimated 39.7% in 2013 at a CAGR of 5.6% (World Bank, 2014j). This is expected to drive the country’s healthcare market.

Singapore’s economy is stable due to continued government initiatives, which are aimed at increasing Foreign Direct Investment (FDI) and attracting investors. These factors are important for the growth of the economy.

The country offers a stable economy for investors due to the stable government and its initiatives. Gross Domestic Product (GDP) per capita of Singapore was $56,113 in 2014 and is expected to increase further to $67,808 in 2020 at a CAGR of 3.2% (IMF, 2014a). This increasing growth in GDP per capita reflects the economic growth.

The unemployment rate decreased from 2.2% in 2008 to 2% in 2013 at a negative CAGR of 1.9% (DoS, 2014). The increase in the employment rate is due to the manufacturing operations of the medical technology and pharmaceuticals sectors under BMS, which have increased the employment opportunities in the country.

In 2014, Business Environment Risk Intelligence (BERI) ranked Singapore first among 50 countries as an investment destination followed by Switzerland and Taiwan (EDB, 2014g). Singapore continues to boost its knowledge-based free market economy, which is primarily dependent upon exports. Singapore provides a corruption-free and open market environment. The country’s exports primarily consist of consumer electronics, information technology products, pharmaceuticals, and on a growing financial services sector (CIA, 2014b).

The government has taken steps to upgrade the skills of the local workforce in order to meet the increasing demands of the domestic market. In 2010, the government launched the Workfare Training Support (WTS) scheme to encourage low-wage workers to undertake training by providing them with subsidies (up to 95% of course fees) and absentee payroll funding ($320 per annum (pa)). In 2011, the government extended the coverage of the Continuing Education and Training (CET) scheme, which was previously available only for low-wage workers, to professionals, managers, executives and technicians.

All of these measures are set to attract major investment in pharmaceuticals, medical technology production and other manufacturing sectors, while maintaining the status of being Southeast Asia's financial and high-tech hub (OECD, 2013).

For more information see – http://mrr.cm/4ZV

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Global diagnostic testing market for sexually transmitted diseases is forecast to reach $167.4 billion by 2020, Finds New Report

"Global Market for Diagnostic Testing of Sexually Transmitted Diseases (STDs) (Disease Types, Testing Volume, Testing Devices and Geography) - Industry Analysis and Forecast, 2013 - 2020", considers commercial aspects of the diagnostic testing of sexually transmitted diseases. Based on key trends tracked, it is anticipated that the diagnostic testing market for sexually transmitted diseases is forecast to reach $167.4 billion by 2020, registering a CAGR of 8.5% during 2014-2020.

The growth in the market is chiefly attributed to the high growth in HIV and HPV testing, especially in Asia Pacificand African regions along with complimenting growth rate of the European market.Sexually transmitted diseases or venereal diseases (VDs) are one of the most critical health challenges facing the world today. Rising rate of incidence of fatal STDs, corresponding high-economic burden and consequent implementation of Provider-Initiated Counselling and Testing (PICT) and Client-Initiated Counselling and Testing (CICT) are factors that drive the growth of the diagnostic testing market for STDs.

Clinical manifestations of STD, for example, Chlamydia range from Urethritis, Epididymitis, Orchitis, Infertility in men to Cervicitis, Endometritis, Salpingitis, PID, infertility and Perihepatitis in women; and untreated STDs that display such manifestations are often fatal. The risk of transmission of Chlamydia infection from an infected male to a female partner is estimated to be about 40% and from an infected female to male is about 30%.

Such high rate of transmission, coupled with high rate of undiagnosed and untreated cases (about 85% of women and 40% of men are asymptomatic), renders huge economic burden on healthcare departments across all countries. To ameliorate such cases, healthcare departments across the world, have initiated national screening and also incentivized voluntary screening.

Overall, the afore-mentioned factors result in high testing volume for Chlamydia, which contributes to a larger market share in terms of value. HIV, is incurable and prognosis of HIV leads to numerous infections that result in fatality. HIV infected patients also suffer from other co-infections; HIV and Syphilis have a high co-infection rate of about 25%. Akin to national and voluntary screening implemented for Chlamydia, many healthcare departments implemented CICT and PICT screening for HIV too. Such screening programs are expected to increase HIV testing volumes, which is estimated to reach 2.1 billion by 2020.

Laboratory testing of STDs is significant, despite of the presence of many point-of-care (PoC) testing kits available. Some of the STDs are not diagnosed with point of care methods. For instance, HSV (Herpes Simplex Virus), low-risk HPV (Human Papilloma Virus) and Chancroid that manifest as 'warts' on the patient's skin, require physical examination by the laboratory experts. Also, many of the PoC devices are not yet approved by the regulatory health authorities such as USFDA, owing to deviations in the sensitivity and specificity criteria. For these reasons, laboratory testing is considered to be most reliable and globally accepted method for STD testing; therefore, garners a comparatively larger market share than POC testing.

The report also provides market size and forecast for testing devices used for carrying such tests. The market for STD testing devices was valued at $7.7 billion in 2013 with laboratory testing devices accounted for the most of the market and PoC devices shall grow at fastest rate.

Key findings of the study:

• Global market for diagnostic testing of STDs is gaining traction with growth in HIV and HPV screening and laboratory testing
• HIV testing market segment would grow at a CAGR of 10.9% during the forecast period
• Europe would be one of the lucrative markets in terms of growth. The European STDs testing market would reach $26.8 billion by 2020, with highest CAGR of 13.5% (as compared to other regional markets)
• HPV testing volume and revenue will grow at much faster rate owing to higher incidences in Asia Pacific region
• As elaborated earlier, many healthcare institutions provide diagnostic testing services for STDs, such as specialized STD clinics, Genito-Urinary Medicine (GUM) clinics along with general hospitals, government laboratories and private diagnostic centres. The afore-mentioned thus constitute key market participants of the global diagnostic testing of STDs market. Along with the testing service providers, many companies provide devices such as laboratory instruments and POC testing kits/devices for VDs. Companies profiled in this report are Roche Holdings AG, BioMerieux, Hologic Inc., Becton Dickinson & Company, Cepheid Inc., Danaher Corporation, Affymetrix, Alere Inc., Abbott Laboratories, Bio-Rad Laboratories Inc., and DiaSorin.

Spanning over 110 pages, 44 Tables and 27 Figures “Global Sexually Transmitted Diseases (STDs) Testing Market (Disease Types, Testing Volume, Testing Devices and Geography) - Industry Analysis and Forecast, 2013 - 2020” report Covering Introduction, Executive Summary, Market Overview, Global Venereal Diseases Diagnostic Testing Market By Disease Type, Global Venereal Diseases Diagnostic Testing Market By Location Of Testing, Global Venereal Diseases Diagnostic Testing Market By Testing Devices, Global Venereal Diseases Diagnostic Testing Market By Geography, Company Profiles. This report Covered 10 Companies - Roche Diagnostics, BioMerieux, Hologic, Inc., Becton Dickinson & Company, Cepheid, Inc., Danaher Corporation, Affymetrix, Inc., Alere, Inc., Abbott Laboratories, DiaSorin.

Know more about this report at – http://mrr.cm/4kN

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

The global neuroprosthetics market is expected to reach $14 billion by 2020, Finds New Report, New Report Launched

"Global Neuroprosthetics Market (Product Types, Technology, Application, and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020", the global neuroprosthetics market is expected to reach $14 billion by 2020, registering a CAGR of 15.8% from 2014 to 2020.

High growth segments such as Visual neuroprosthetics/retinal implants and applications such as Parkinson's disease, Overactive Bladder Syndrome and Epilepsy are expected to contribute substantially to the growth of the overall global Neuroprosthetics market. Motor Prosthetics holds the largest share within Neuroprosthetics devices market segment whereas Sacral Cord Stimulation (SCS) would maintain the leading market position through 2020, within technology segment.Multitude of cognitive and physiological disorders have a debilitating impact on 'quality-of-life' of affected patient populace.

A majority (~80%) of such patients are unamenable to any form of treatment as first line (drug) and second line (invasive surgeries) treatments fail. Neuroprosthetics devices or neural implants or brain implants offer an efficacious solution to the afore-mentioned type of patients. Neuroprosthetics deploy technologies such as Deep Brain Simulation (DBS), Vagus Nerve Stimulation (VNS), Spinal Cord Stimulation (SCS) and Sacral Nerve Stimulation (SNS) depending on the clinical condition to ameliorate the disease condition. Depending on the condition treated, product types of Neuroprosthetics include Motor Prosthetics, Auditory Prosthetics/ Cochlear Implants, Visual Prosthetics/ Retinal implants and Cognitive Prosthetics.

Owing to various factors such as high base of affected patient population, the patient population amenable to Neuroprosthetics and scope of improvement in QALY, the Motor Neuroprosthetics market for treating Parkinson's disease garners the largest market share; Motor Neuroprosthetics for treating Overactive Bladder Syndrome and Motor Neuroprosthetics for treating Epilepsy are second and third largest segment respectively. Despite such benefits that are high-impact growth drivers for the market, high-cost of devices curtail the adoption rate by patients, thus restrain the market growth.

Key findings of the study:

• Global market for Neuroprosthetics gaining traction with Visual Prosthetics/ Retinal implants and Motor Neuroprosthetics (for treating Parkinson's disease) being major growth arenas during the forecast period (2014 - 2020)
• Within Neuroprosthetics devices market, Visual Prosthetics/ Retinal implants is the fastest growing segment
• Within Neuroprosthetics devices, Motor Neuroprosthetics segment would garner the largest market share, owing to numerous applications such as Parkinson's disease, Neurocardiac disorders, Over Active Bladder syndrome and Epilepsy
• North America would be the lucrative market, both in terms of market size and growth, (among all regional markets)

Spanning over 156 pages, 42 Tables and 37 Figures “Global Neuroprosthetics Market (Product Types, Technology, Application, and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020” report Covering Introduction, Executive Summary, Market Overview, Global Neuroprosthetics Market By Technology, 2013-2020, $Million, Global Neuroprosthetics Market By Type, 2013-2020, $Million, Global Neuroprosthetics Market By Application, 2013-2020, $Million, Global Neuroprosthetics Market By Geography, 2013-2020, $Million, Company Profiles. This report Covered These Companies - Boston Scientific Corporation, Cochlear Limited, Cyberonics Inc., Medtronic Inc., NDI Medical LLC, Nervo Corp., NeuroPace Inc, Retina Implant AG, Jude Medical, Sonova Group (Advanced Bionics AG).

Know more about this report at – http://mrr.cm/4k5

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare